Press Releases

Latest

Lokelma demonstrated efficacy in treating hyperkalaemia in patients with end-stage renal disease on haemodialysis
14 June 2019
Calquence Phase III ELEVATE-TN trial met primary endpoint at interim analysis in previously-untreated chronic lymphocytic leukaemia
6 June 2019
Lynparza achieved a 72% objective response rate in patients with relapsed, germline BRCA-mutated advanced ovarian cancer
3 June 2019
Lynparza nearly doubled the time patients lived without disease progression from germline BRCA-mutated metastatic pancreatic cancer
3 June 2019
Imfinzi is the only immunotherapy to demonstrate overall survival at three years in unresectable Stage III non-small cell lung cancer
2 June 2019
New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever
20 May 2019
New data on Symbicort as a potential anti-inflammatory reliever in mild asthma to be presented at ATS 2019
16 May 2019
AstraZeneca continues to redefine cancer treatment at the 2019 ASCO Annual Meeting
16 May 2019
Pooled analyses of the roxadustat global Phase III programme confirmed cardiovascular safety
10 May 2019
Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer, a population with high unmet need
8 May 2019

Can't find what you are looking for? Our Press Release archive contains all of our press releases dated before 2018 so you should be able to find just what you are looking for.

Explore archive

Contact us

Gonzalo Viña

Head of Global Media Relations

+44 203 749 5916

Rob Skelding

Director Global Media Relations

+44 203 749 5821

Matthew Kent

Director Global Media Relations

+44 203 749 5906

Rebecca Einhorn

Director Global Media Relations

+1 301 398 1802

Jennifer Hursit

Manager Global Media Relations

+442037495762

Christina Malmberg Hägerstrand

Media Relations Director, Sweden and Nordic-Baltic

+46 8 552 53 106

Lotta Sjösten

Manager Media Relations, Sweden

+46 8 553 271 10

US Media Team

+1 302 885 2677

Press Releases

Contact us

Subscribe

Follow us

LinkedIn